In non-small-cell lung cancer (NSCLC), SNHG3 activation by E2F1 drives proliferation and migration via the TGF-β and IL-6/JAK2/STAT3 pathways, underscoring its therapeutic relevance [33]. The gene discussed is JAK2; the disease is non-small cell lung carcinoma.